Cargando…

Correction: Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis—A Meta-Analysis

Detalles Bibliográficos
Autores principales:	Fisher, Anat, Bassett, Ken, Goel, Gautam, Stanely, Dana, Brookhart, M. Alan, Freeman, Hugh J., Wright, James M., Dormuth, Colin R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2017
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5310890/ https://www.ncbi.nlm.nih.gov/pubmed/28199406 http://dx.doi.org/10.1371/journal.pone.0172646

Ejemplares similares

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis
por: Fisher, Anat, et al.
Publicado: (2016)

Prescriber preference for a particular tumour necrosis factor antagonist drug and treatment discontinuation: population-based cohort
por: Fisher, Anat, et al.
Publicado: (2014)

Comparative Persistence of the TNF Antagonists in Rheumatoid Arthritis – A Population-Based Cohort Study
por: Fisher, Anat, et al.
Publicado: (2014)

Frequency and predictors of tablet splitting in statin prescriptions: a population-based analysis
por: Dormuth, Colin R, et al.
Publicado: (2008)

A cluster randomized trial assessing the impact of personalized prescribing feedback on antibiotic prescribing for uncomplicated acute cystitis to family physicians
por: Carney, Greg, et al.
Publicado: (2023)

Policy‐induced selection bias in pharmacoepidemiology: The example of coverage for Alzheimer's medications in British Columbia
por: Fisher, Anat, et al.
Publicado: (2019)

Is It Possible to Discontinue Tumor Necrosis Factor Antagonists after Psoriasis Remission?
por: Kim, Byungsoo, et al.
Publicado: (2019)

Mandatory nonmedical switching from originator to biosimilar infliximab in patients with inflammatory arthritis and psoriasis in British Columbia: a cohort study
por: Fisher, Anat, et al.
Publicado: (2022)

Comparison of drug survival rates for tumor necrosis factor antagonists in rheumatoid arthritis
por: Martínez-Santana, Virginia, et al.
Publicado: (2013)

Is thiazolidinediones use a factor in delaying the need for insulin therapy in type 2 patients with diabetes? A population-based cohort study
por: Carney, Greg A, et al.
Publicado: (2012)

Monitoring a Mandatory Nonmedical Switching Policy from Originator to Biosimilar Infliximab in Patients with Inflammatory Bowel Diseases: A Population-Based Cohort Study
por: Fisher, Anat, et al.
Publicado: (2023)

Trends in antihypertensive drug utilization in British Columbia, 2004–2019: a descriptive study
por: Kim, Jason D., et al.
Publicado: (2023)

The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study
por: Wu, Chun-Ying, et al.
Publicado: (2014)

Sinus aspergilloma in rheumatoid arthritis before or during tumor necrosis factor-alpha antagonist therapy
por: Leboime, Ariane, et al.
Publicado: (2009)

Rapid monitoring of health services use following a policy to switch patients from originator to biosimilar etanercept—a cohort study in British Columbia
por: Fisher, Anat, et al.
Publicado: (2022)

Erratum to: The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study
por: Wu, Chun-Ying, et al.
Publicado: (2016)

Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
por: Dormuth, Colin R., et al.
Publicado: (2009)

Correction: Rosiglitazone and Myocardial Infarction in Patients Previously Prescribed Metformin
por: Dormuth, Colin R., et al.
Publicado: (2010)

Outcomes associated with hospital admissions for accidental opioid overdose in British Columbia: a retrospective cohort study
por: Morrow, Richard L, et al.
Publicado: (2019)

Impact of rosiglitazone meta-analysis on use of glucose-lowering medications
por: Morrow, Richard L, et al.
Publicado: (2010)

Comparison of cholinesterase inhibitor safety in real-world practice
por: Carney, Greg, et al.
Publicado: (2019)

Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis
por: Karpes Matusevich, Aliza R, et al.
Publicado: (2021)

Response to Biologic Disease-Modifying Anti-Rheumatic Drugs after Discontinuation of Anti-Tumor Necrosis Factor Alpha Agents for Rheumatoid Arthritis
por: Bergman, Martin J., et al.
Publicado: (2014)

Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis
por: van Vollenhoven, Ronald F, et al.
Publicado: (2016)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

Tapering and discontinuation of glucocorticoids in patients with rheumatoid arthritis treated with tofacitinib
por: Spinelli, Francesca Romana, et al.
Publicado: (2023)

Effects of Tumour Necrosis Factor Antagonists on Insulin Sensitivity/Resistance in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
por: Burska, Agata N., et al.
Publicado: (2015)

Nirmatrelvir-Ritonavir and COVID-19 Mortality and Hospitalization Among Patients With Vulnerability to COVID-19 Complications
por: Dormuth, Colin R., et al.
Publicado: (2023)

Discontinuation and reinitiation patterns of osteoporosis treatment among commercially insured postmenopausal women
por: Balasubramanian, Akhila, et al.
Publicado: (2013)

Factors associated with successful discontinuation of certolizumab pegol in early rheumatoid arthritis
por: Tanaka, Yoshiya, et al.
Publicado: (2020)

Factors predicting pain and early discontinuation of tumour necrosis factor-α-inhibitors in people with rheumatoid arthritis: results from the British society for rheumatology biologics register
por: McWilliams, Daniel F., et al.
Publicado: (2016)

Acute anterior uveitis after discontinuation of tocilizumab in a patient with rheumatoid arthritis
por: Sato, Tomohito, et al.
Publicado: (2014)

Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry
por: Strand, Vibeke, et al.
Publicado: (2017)

What is the future of CCR5 antagonists in rheumatoid arthritis?
por: Takeuchi, Tsutomu, et al.
Publicado: (2012)

Influence of tumor necrosis factor α in rheumatoid arthritis
por: Kulp, Werner, et al.
Publicado: (2005)

Comparison of the drug retention and reasons for discontinuation of tumor necrosis factor inhibitors and interleukin-6 inhibitors in Japanese patients with elderly-onset rheumatoid arthritis—the ANSWER cohort study
por: Jinno, Sadao, et al.
Publicado: (2021)

Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation
por: Zhuang, Hongqing, et al.
Publicado: (2016)

Reasons for discontinuation of subcutaneous biologic therapy in the treatment of rheumatoid arthritis: a patient perspective
por: Bolge, Susan C, et al.
Publicado: (2015)

Comparison of Biologic Discontinuation in Patients With Elderly‐Onset Versus Younger‐Onset Rheumatoid Arthritis
por: Richter, Michael D., et al.
Publicado: (2019)

Prevalence and predictors of sustained remission/low disease activity after discontinuation of induction or maintenance treatment with tumor necrosis factor inhibitors in rheumatoid arthritis: a systematic and scoping review
por: Ward, Michael M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c2p97dqtp3kr9la7scc31hl7qq